Migraine Clinical Trial Tracker — Stay Current on CGRP, Gepants, and Beyond

Why migraine trial monitoring matters

Migraine affects approximately 39 million Americans and over 1 billion people worldwide, making it one of the leading causes of disability globally. Despite this massive burden, the field was largely stagnant for decades — until the CGRP era rewrote the treatment paradigm beginning in 2018. The approvals of erenumab, fremanezumab, galcanezumab, and eptinezumab as preventive monoclonal antibodies, followed by ubrogepant, rimegepant, and lasmiditan for acute treatment, triggered an industry-wide expansion in migraine clinical development that continues to accelerate.

With hundreds of active migraine trials on ClinicalTrials.gov spanning both acute and preventive indications, systematic monitoring is essential for CNS pharma teams, neurology investors, and headache medicine researchers. Key signals to track:

• Next-generation CGRP receptor antagonists (gepants) — new molecules, extended indications, combination approaches
• PACAP (pituitary adenylate cyclase-activating polypeptide) pathway inhibitors — the most anticipated emerging target in migraine prevention
• Novel acute treatment mechanisms beyond triptans and ditans
• Non-invasive neurostimulation device trials (external trigeminal nerve stimulation, vagus nerve stimulation)
• Chronic migraine vs episodic migraine trials — distinct patient populations with different endpoints
• Pediatric and adolescent migraine programs — an underserved population with growing regulatory attention
• Comorbidity trials studying migraine in the context of depression, anxiety, and sleep disorders

What we monitor for migraine

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a migraine watch profile, you can configure:

• Condition keywords: "migraine", "chronic migraine", "episodic migraine", "migraine with aura", "migraine prevention", "migraine prophylaxis", "cluster headache"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The migraine treatment landscape in 2026

CGRP monoclonal antibodies: the established prevention standard

The four approved CGRP-targeting monoclonal antibodies — erenumab (Aimovig, Amgen/Novartis), fremanezumab (Ajovy, Teva), galcanezumab (Emgality, Eli Lilly), and eptinezumab (Vyepti, Lundbeck) — have established CGRP inhibition as the dominant mechanism for migraine prevention. Clinical development continues with head-to-head comparison trials, long-term extension studies examining multi-year durability, and novel patient population studies in menstrual migraine, vestibular migraine, and high-frequency episodic migraine. Real-world evidence studies are increasingly registering alongside traditional RCTs.

Gepants: oral CGRP antagonists for acute and preventive use

The oral CGRP receptor antagonists — ubrogepant (Ubrelvy, AbbVie) and rimegepant (Nurtec ODT, Pfizer) for acute treatment, with rimegepant also approved for prevention — represent a significant advance over triptans for patients with cardiovascular contraindications. Atogepant (Qulipta, AbbVie) extended gepant utility into the preventive setting, and the competitive gepant pipeline remains active with new molecules and combination programs in development. Monitoring gepant trial registrations tracks the competitive dynamics in the highest-growth segment of the migraine market.

5-HT1F agonists: ditans as a distinct acute treatment class

Lasmiditan (Reyvow, Eli Lilly), the first approved ditan, targets the 5-HT1F receptor without causing vasoconstriction — a key differentiation from triptans in cardiovascular-risk patients. Clinical programs investigating lasmiditan in new populations, comparing it to gepants, and exploring combination approaches continue to register. The class may expand if additional 5-HT1F agonist programs advance through Phase 2 development.

PACAP pathway: the next frontier in migraine prevention

Pituitary adenylate cyclase-activating polypeptide (PACAP) has emerged as perhaps the most promising new target in migraine neurobiology. PACAP-38 infusion reliably triggers migraine-like attacks in susceptible individuals, and antibodies targeting PACAP or its PAC1 receptor are advancing through Phase 2 trials. AMG 301 (Amgen's PAC1 antibody) reached Phase 2 before setbacks, but the mechanistic rationale remains strong and competitor programs continue. Tracking PACAP trial registrations provides early visibility into what may become the next generation of migraine prevention.

GluN2B and other CNS targets

Beyond CGRP and PACAP, researchers are investigating glutamate receptor antagonism, calcitonin gene-related peptide receptor modulation, and trigeminovascular pathway targets. GluN2B (NR2B) subunit-selective NMDA receptor antagonists have shown early promise in central sensitization models relevant to chronic migraine. These exploratory programs are predominantly in Phase 1 and early Phase 2, but tracking their registration gives insight into early-stage pipeline directions.

Neuromodulation devices

FDA-cleared neurostimulation devices — including Cefaly (external trigeminal nerve stimulation), gammaCore (vagus nerve stimulation), and the SpringTMS transcranial magnetic stimulation device — have generated regulatory interest in non-pharmacological approaches. Sham-controlled device trials are increasingly registering on ClinicalTrials.gov, particularly for chronic migraine patients inadequate to pharmacological prevention.

Who uses migraine trial monitoring

CNS pharma and biotech companies

Companies with migraine programs — including AbbVie, Pfizer, Eli Lilly, Teva, Lundbeck, and emerging biotechs — monitor competitor trial activity to inform their own development strategies. BD teams track new Phase 1 and Phase 2 registrations to identify potential acquisition targets and licensing opportunities in the CGRP and post-CGRP pipeline space.

Headache medicine specialists and academic centers

Headache medicine neurologists at academic medical centers and dedicated headache clinics track new trial registrations to identify patient enrollment opportunities, stay current on emerging mechanisms, and understand where the field is heading before clinical data become publicly available. Migraine is one of the most trial-active neurological conditions.

Neurology-focused investors

Investors with CNS exposure monitor migraine trial activity as an indicator of competitive dynamics in the CGRP market and the emerging PACAP space. Trial registrations for next-generation gepants, new prevention mechanisms, or PACAP pathway agents often represent the earliest public signal of a company's pipeline priorities, preceding investor day presentations or conference abstracts by 6–18 months.

Frequently asked questions

How current is the migraine trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track acute treatment and prevention trials separately?

Yes. On the Pro plan ($149/month), you can create multiple search profiles. You might have one profile for acute migraine treatment trials, another for CGRP prevention programs, and another for PACAP pathway trials — each delivering a focused daily digest.

Does this cover international migraine trials?

ClinicalTrials.gov includes trials conducted internationally, so yes — global migraine trials registered on the platform are included. Industry-sponsored programs with US sites, which represent the majority of commercial development activity, are systematically registered here.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic RSS-style alerts without phase filtering, sponsor type filtering, or organized digest formatting. We provide filtered, labeled, and organized alerts — the intelligence layer on top of the raw registry data.

Can I track cluster headache trials alongside migraine?

Yes. Cluster headache trials often register alongside migraine programs, particularly for CGRP-targeting agents. You can add "cluster headache" as a keyword to your search profile to capture both conditions in a single digest.